Characteristic Ber-EP4 and EMA expression in sebaceoma is immunohistochemically distinct from basal cell carcinoma

Histopathology

Volumn 51, Issue 1, 2007, Pages 80-86

  Fan, Y S ^a   Carr, R A ^b   Sanders, D S A ^b   Smith, A P ^b   Lazar, A J F ^c   Calonje, E ^d  

^a QUEEN MARY HOSPITAL   (Hong Kong)

^b WARWICK HOSPITAL   (United Kingdom)

^c UNIVERSITY OF TEXAS   (United States)

^d ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

Basal cell carcinoma; Ber EP4; Epithelial membrane antigen; Immunohistochemistry; Sebaceoma

Indexed keywords

EPITHELIAL MEMBRANE ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY BER EP4; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CELL MATURATION; CONTROLLED STUDY; CYTOPLASM; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; KERATOSIS; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEBACEOUS GLAND TUMOR; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; BIOPSY; CA-15-3 ANTIGEN; CARCINOMA, BASAL CELL; DIAGNOSIS, DIFFERENTIAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, ADNEXAL AND SKIN APPENDAGE; SEBACEOUS GLANDS; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

ZIZIPHUS MAURITIANA;

EID: 34250860261     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02722.x     Document Type: Article

References (21)

1. Sloane JP, Ormerod MG. Distribution of epithelial membrane antigen in normal and. neoplastic tissue and its value in diagnostic tumour pathology. Cancer 1981 47 1787 1795.
2. Misago N, Suse T, Uemura T et al. Basal cell carcinoma with sebaceous differentiation. Am. J. Dermatopathol. 2004 26 298 303.
3. Misago N, Mihara I, Ansai S-I, Narisawa Y. Sebaceous and related neoplasms with sebaceous differentiation. A clinicopathologic study of 30 cases. Am. J. Dermatopathol. 2002 24 294 304.
4. Brownstein MH, Shapiro L. The pilosebaceous tumors. Int. J. Dermatol. 1977 16 340 352.
5. Latza U, Niedobitek G, Schwarting R et al. Ber-EP4: new monoclonal antibody which distinguishes epithelia from mesothelial. J. Clin. Pathol. 1990 43 213 219.
6. Jimenez FJ, Burchette JL Jr., Grichnik JM et al. Ber-EP4 immunoreactivity in normal skin and cutaneous neoplasms. Mod. Pathol. 1995 8 854 858.
7. Tellechea O, Reis JP, Domingues JC, Baptista AP. Monoclonal antibody Ber EP4 distinguishes basal-cell carcinoma from squamous-cell carcinoma of the skin. Am. J. Dermatopathol. 1993 15 452 455.
8. Beer TW, Shepherd P, Theaker JM. Ber EP4 and epithelial membrane antigen aid distinction of basal cell, squamous cell and basosquamous carcinoma of the skin. Histopathology 2000 37 218 223.
9. Rulon DB, Helwig EB. Cutaneous sebaceous neoplasms. Cancer 1974 33 82 102.
10. Troy JL, Ackeraman AB. Sebaceoma. A distinctive benign neoplasm of adnexal tumour differentiating towards sebaceous cell. Am. J. Dermatopathol. 1984 6 7 13.
11. Sinard JH. Immunohistochemical distinction of ocular sebaceous carcinoma from basal cell and squamous cell carcinoma. Arch. Opthalmol. 1999 117 776 783.
12. Johnson JS, Lee JA, Cotton DWK et al. Dimorphic immunohistochemical staining in ocular sebaceous neoplasms: a useful diagnostic aid. Eye 1999 13 104 108.
13. Ansai S, Hashiomoto H, Aoki T et al. A histochemical and immunohistochemical study of extra-ocular sebaceous carcinoma. Histopathology 1993 22 127 33.
14. Misago N, Kodera H, Narisawa Y. Sebaceous carcinoma, trichoblastoma, and sebaceoma with features of trichoblastoma in nevus sebaceus. Am. J. Dermatopathol. 2001 23 456 462.
15. Bayer-Garner IB, Givens V, Smoller B. Immunohistochemical staining for androgen receptors. A sensitive marker of sebaceous differentiation. Am. J. Dermatopathol. 1999 21 426 431.
16. Burgdorf WHC, Pitha J, Fahmy A. Muir-Torre syndrome. Histologic spectrum of sebaceous proliferations. Am. J. Dermatopathol. 1986 8 202 208.
17. Rütten A, Burgdorf W, Hügel H et al. Cystic sebaceous tumours as marker lesions for the Muir-Torre syndrome. Am. J. Dermatopathol. 1999 21 405 413.
18. Schwartz RA, Torres DP. The Muir-Torre syndrome: a 25 year retrspect. J. Am. Acad. Dermatol. 1995 33 90 104.
19. Machin P, Catasus L, Pons C et al. Microsatellite instability and immunostaining for MSH-2 and MLH-1 in cutaneous and internal tumours from patients with the Muir-Torre syndrome. J. Cutan. Pathol. 2002 29 415 420.
20. Marthiak MR, Rutten A, Mangold E et al. Loss of DNA mismatch repair proteins in skin tumours from patients with Muir-Torres syndrome and MSH2 or MLH1 germline mutations: establishment of immunohistochemical analysis as a screening test. Am. J. Surg. Pathol. 2002 26 338 343.
21. Boland CR, Thibodeau SN, Hamilton SR et al. A National Cancer Institute Workshop on microsatellite instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998 58 5248 5257.